Share

The 1500th patient has been enrolled in the E²-RADIatE cohort OLIGOCARE (RP-1822)

It is a great pleasure to announce that the 1500th patient has been enrolled in the OligoCare cohort of the 1811-E2-RADIatE platform. The milestone was reached on the 25th of July and the patient was enrolled by the team of Professor Kaouthar Khanfir (Hopital du Valais – Hopital de Sion).

The first patient was registered in August 2019. To date, the cohort has an average recruitment of 60 patients/month.

We warmly thank all Investigators that have so far contributed to the success of this cohort, with particular recognition to the top three recruiting investigators, Prof. Filippo Alongi, Prof. Marta Scorsetti and Prof. Umberto Ricardi.

We continue working on opening more sites in the platform to enrol patients in the OligoCare cohort.

The E2-RADIatE platform is an observational prospective multi-cohort study that collects real-world data of cancer patients treated with radiotherapy. It currently includes two cohorts, OligoCare and ReCare:

  • OligoCare includes patients with oligometastatic cancer
  • ReCare will include patients treated with high-dose re-irradiation

The development of cohort RP-2011 ReCare, is almost complete. Once the protocol is released (expected by September 2022), 26 sites will be able to enrol patients in the cohort after regulatory approvals and operational steps have been fulfilled.

Furthermore, in order to increase enrolment and data collection, we are exploring the interest in this cohort from sites already participating in OligoCare.

Thank you to all the participating centres and patients that have so far contributed to Oligocare,

The EORTC 1822 study team

Back to news list

Related News

  • EORTC Quality of Life Group’s participation to ISOQOL 2024

  • New Insights into Glioblastoma Treatment for Older Adults Patients

  • TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival

  • New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024

  • Late Breaking Results from the EORTC 1333/PEACE III phase III trial

  • EORTC’s presence at ESMO 2024

  • Meet the new EORTC Board

  • We are pleased to announce the release of the EORTC 2023 Annual Report

  • Dr Denis Lacombe, EORTC CEO, appointed stakeholder co-chair of ACT EU advisory group

  • Clinical Trials Day 2024: a Q&A on pragmatic clinical trials